|
|
Transparency notification BlackRock, Inc.Notification referring to situation on 3 July 2019Threshold crossed: 5%Latest holding: 5.06 %Brussels Belgium, 9 July 2019 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from... See more |
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.Notifications referring to situation on 24 June 2019 and 27 June 2019Threshold crossed: 5%Latest holding: 5.27%Brussels Belgium, 1 July 2019 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received two... See more |
|
| |
|
| |
|
|
UCB and Amgen Provide Regulatory Update on Status of EVENITY® romosozumab in the EUBrussels, Belgium and Thousand Oaks, Calif. 28 June – UCB Euronext Brussels: UCB and Amgen NASDAQ:AMGN today announced the companies have been informed that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a negative opinion on the Marketing Authorisation... See more |
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.Notifications referring to situation on 18 June 2019 and 19 June 2019Threshold crossed: 5%Latest holding: 5.26%Brussels Belgium, 24 June 2019 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received two... See more |
|
| |
|
| |
|
|
UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis PatientsNew Phase 2b bimekizumab data showed the novel investigational molecule delivered improvements in disease activity and in important patientreported outcomes, such as pain, fatigue, morning stiffness, function and quality of life for patients with ankylosing spondylitis.Improvements are... See more |
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.Notifications referring to situation on 5 June 2019 and 7 June 2019Threshold crossed: 5%Latest holding: 5.23%Brussels Belgium, 12 June 2019 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received two... See more |
|
| |
|
| |
|
|
UCB Showcases the Depth of its Immunology Research and Commitment to Patientsat EULAR 2019Three oral presentations on novel investigational molecule bimekizumab to show potential for improving disease activity and quality of life outcomes in patients with ankylosing spondylitis, and musculoskeletal and skin outcomes over 48 weeks in those with psoriatic arthritisMultiple presentations will... See more |
|
| |
|
| |
Search :
